APP and Alzheimer disease: In addition, as previous studies identified elevated levels of MS4A6A is associated with risks of AD onset in humans [19] and elevated expression of Ms4a6d in APP/PS1 mouse [15], we found that there is an increased expression level of Ms4a6d as mice age (Fig. 1g), which could represent a compensatory mechanism to promote amyloid clearance.